Product
Supplier
Encyclopedia
Inquiry
Home > News > Policy & Regulation > India: Dr. Reddy's Gets 4 Observations from USFDA for Telangana Plant

India: Dr. Reddy's Gets 4 Observations from USFDA for Telangana Plant

Chemical Weekly 2018-04-08

Dr. Reddy’s Laboratories has said that the US health regulator had issued four observations after inspecting its active pharmaceutical ingredients (API) facility in Telangana. “The audit of our API Hyderabad plant 1 at Jinnaram Mandal, Medak district, Telangana, by the USFDA has been completed. We have been issued a Form 483 with four observations, which will be addressed comprehensively within stipulated time,” Dr. Reddy’s said in a regulatory filing.

According to the USFDA, a Form 483 is issued to a firm’s management at the conclusion of an inspection when investigator has observed any condition that in its judgement may constitute a violation of the Food Drug and Cosmetic (FD&C) Act and related Acts. It notifies the company’s management of objectionable conditions.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.